Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV

Inclusion Criteria: * HIV-1 infection * Receipt of antiretroviral therapy for at least 6 months * Sexually active in the past 6 months; sexual activity is defined as insertive penile-vaginal sex, receptive or insertive penile-anal sex, oral-anal sex, or oral-genital sex Willingness to comply with three-dose vaccine schedule and subsequent six-month visits for up to four years after randomization. Exclusion Criteria: * Have a history of oropharyngeal cancer (OPC) or other HPV-related cancer or have suspected OPC or other HPV-related cancer; * Have received any doses of a licensed or experimental HPV vaccine or have participated in an HPV vaccine study, * Have a history of anaphylaxis to vaccines or are allergic to any vaccine component (e.g.aluminum, yeast, benzonase); * Have received any blood products within six months of enrollment, or are currently taking immune-suppressants. * Currently have warts/lesions in the oral cavity. * Plan to relocate during the study period. * Have AIDS-defining condition within 6 months prior to study entry.